Summary
15.83 0.34(2.20%)07/01/2024
Catalyst Pharmaceuticals Inc (CPRX)
Catalyst Pharmaceuticals Inc (CPRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.20 | -0.64 | -6.55 | -2.82 | -10.00 | 16.04 | 303.13 | 153.77 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 15.83 | |
| Open | 15.52 | |
| High | 15.97 | |
| Low | 15.49 | |
| Volume | 426,051 | |
| Change | 0.34 | |
| Change % | 2.20 | |
| Avg Volume (20 Days) | 716,854 | |
| Volume/Avg Volume (20 Days) Ratio | 0.59 | |
| 52 Week Range | 11.55 - 17.50 | |
| Price vs 52 Week High | -9.54% | |
| Price vs 52 Week Low | 37.06% | |
| Range | 1.98 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,830 | |
| EBIDTA | 114,040,000 | |
| PE Ratio | 28.4643 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 27.00 | |
| Book Value | 4.7570 | |
| Earnings Per Share | 0.5600 | |
| EPS Estimate Current Quarter | 0.1700 | |
| EPS Estimate Next Quarter | 0.2400 | |
| EPS Estimate Current Year | 1.0000 | |
| EPS Estimate Next Year | 1.4900 | |
| Diluted EPS (TTM) | 0.5600 | |
| Revenues | ||
| Profit Marging | 0.1583 | |
| Operating Marging (TTM) | 0.2754 | |
| Return on asset (TTM) | 0.0929 | |
| Return on equity (TTM) | 0.1455 | |
| Revenue TTM | 411,347,008 | |
| Revenue per share TTM | 3.7710 | |
| Quarterly Revenue Growth (YOY) | 0.1540 | |
| Quarterly Earnings Growth (YOY) | -0.2690 | |
| Gross Profit (TTM) | 160,021,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 28.4643 | |
| Forward PE | 10.3520 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.6306 | |
| Revenue Enterprise Value | 4.1739 | |
| EBITDA Enterprise Value | 13.8859 | |
| Shares | ||
| Shares Outstanding | 118,115,000 | |
| Shares Float | 101,887,248 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 6.21 | |
| Institutions (%) | 76.49 | |
06/07 12:36 EST - zacks.com
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
05/30 13:41 EST - globenewswire.com
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for the treatment of Lambert-Eaton myasthenic syndrome (“LEMS”). The increased maximum daily dose offers healthcare providers and patients greater flexibility in treatment regimens for the management of LEMS.
05/28 08:03 EST - globenewswire.com
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.
05/15 08:00 EST - fool.com
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
Growth stocks have been steadily marching higher since the 2008 financial crisis. Even so, there are still plenty of compelling bargains in the space.
05/10 09:30 EST - investors.com
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
05/09 12:41 EST - zacks.com
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
05/09 10:52 EST - seekingalpha.com
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Jason Gerberry - Bank of America Joe Catanzaro - Piper Sandler Operator Greetings, and welcome to the Catalyst Pharmaceuticals' First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Jason Gerberry - Bank of America Joe Catanzaro - Piper Sandler Operator Greetings, and welcome to the Catalyst Pharmaceuticals' First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
05/08 17:08 EST - investors.com
Top 10% Biotech Stock Catalyst Pharma Doubles Wall Street's Profit Views
Catalyst Pharmaceuticals doubled Wall Street's earnings expectations late Wednesday, and the biotech stock recovered from an earlier slide.
Top 10% Biotech Stock Catalyst Pharma Doubles Wall Street's Profit Views
Catalyst Pharmaceuticals doubled Wall Street's earnings expectations late Wednesday, and the biotech stock recovered from an earlier slide.
05/08 16:16 EST - globenewswire.com
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products
05/01 11:07 EST - zacks.com
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/25 01:00 EST - globenewswire.com
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
04/24 13:45 EST - investorplace.com
Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026
Investing in discounted stocks for big gains is a time-tested strategy. Although short-term market fluctuations may capture the attention of many, companies with sustainable growth prospects often prove to be the most lucrative investments over time.
Dirt-Cheap Delights: 3 Discounted Stocks That Could Triple by 2026
Investing in discounted stocks for big gains is a time-tested strategy. Although short-term market fluctuations may capture the attention of many, companies with sustainable growth prospects often prove to be the most lucrative investments over time.
04/22 08:00 EST - globenewswire.com
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET The Company will Host a Conference Call and Webcast on Thursday, May 9, 2024, at 8:30 AM ET
04/05 20:29 EST - youtube.com
Jim Cramer lays out his top small-cap healthcare picks
'Mad Money' host Jim Cramer shares his small-cap healthcare stock picks.
Jim Cramer lays out his top small-cap healthcare picks
'Mad Money' host Jim Cramer shares his small-cap healthcare stock picks.
04/05 18:51 EST - cnbc.com
Jim Cramer recommends five small-cap health-care stocks
CNBC's Jim Cramer said he thinks it could be a good year for small cap stocks and shared his top picks.
Jim Cramer recommends five small-cap health-care stocks
CNBC's Jim Cramer said he thinks it could be a good year for small cap stocks and shared his top picks.
03/29 12:37 EST - zacks.com
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
03/28 08:03 EST - globenewswire.com
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the LEMS community. The chosen date holds profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton's pioneering research on LEMS, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder.
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome ("LEMS") Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the LEMS community. The chosen date holds profound historical significance, coinciding with the publication of Dr. Edward Lambert and Dr. Lee Eaton's pioneering research on LEMS, which has greatly advanced the understanding and treatment of this rare neuromuscular disorder.
03/27 08:03 EST - globenewswire.com
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst's management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.
03/27 07:44 EST - investorplace.com
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
Biotech has seen its fair share of ups and downs, including a massive surge during the pandemic followed by a considerable dip. However, the industry will never go too far away from center stage as diseases and conditions will always need medicine and technology to treat them.
03/18 20:01 EST - investorplace.com
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.